The chart below shows how ARE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ARE sees a -1.03% change in stock price 10 days leading up to the earnings, and a -0.49% change 10 days following the report. On the earnings day itself, the stock moves by +0.07%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
FFO Per Share Growth: Almost 6% FFO per share growth achieved in a challenging macro environment, demonstrating resilience and operational strength.
Revenue and EBITDA Growth: Total revenues and adjusted EBITDA increased by 8% and 11.6% respectively over 2023, driven by solid same property performance and execution of development strategies.
Leasing Volume Increase: Leasing volume for the year reached 5,053,954 square feet, a 17.3% increase from the previous year, indicating strong demand and tenant retention.
Transaction Volume Highlights: The company executed over $1,100,000,000 in transactions during Q4, contributing to a total of approximately $1,400,000,000 for the year, showcasing effective capital recycling efforts.
Dividend Growth Rate: The average annual increase in dividends per share has been 5.4% since 2020, reflecting strong cash flow management and commitment to returning value to shareholders.
Negative
Low Leasing Activity: Development and redevelopment leasing activity for Q4 was low at 13,000 square feet, indicating lingering conservatism from life science company boards and a delay in expansion plans.
Leasing Challenges Ahead: Projects expected to fully deliver in 2025-2026 are only 89% and 70% leased or under negotiations, while projects delivering in 2027 or beyond are just 15% leased or under negotiation, highlighting a significant leasing challenge ahead.
NOI Growth Decline Projected: Same property NOI growth for 2025 is projected to decline by 2% and remain flat on a cash basis, reflecting anticipated challenges in maintaining revenue levels amid lease expirations.
Asset Impairment Losses: In Q4, impairments aggregating $186 million were recognized, primarily related to properties sold and land parcels, indicating a significant loss in asset value.
Occupancy Guidance Challenges: The occupancy midpoint guidance for year-end 2025 is set at 92.4%, which includes approximately 2% vacancy from key projects, suggesting potential challenges in maintaining occupancy levels.
Earnings call transcript: Alexandria RE Q4 2024 misses EPS estimates
ARE.N
0.05%